Award Number:  
W81XWH-08-1-0183

TITLE:  
Molecular Basis of Autophagic Cell Death in Prostate Cancer

PRINCIPAL INVESTIGATOR:  
Ramesh Kaini

CONTRACTING ORGANIZATION:  
University of New Mexico  
Albuquerque, NM, 87131-0001

REPORT DATE:  
March 2009

TYPE OF REPORT:  
Annual Summary

PREPARED FOR:  U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT:  (Check one)

☐ X  Approved for public release; distribution unlimited

☐ Distribution limited to U.S. Government agencies only; report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
# Molecular Basis of Autophagic Cell Death in Prostate Cancer

To understand the molecular basis of autophagy in prostate cancer, I am trying to isolate pure autophagosomes from autophagic cell survival and autophagic cell death. Prostate cancer cell model and profile proteins and lipids to identify autophagy abundant/specific proteins and lipid molecule that are essential for functional autophagy in prostate cancer. I established EGFP.LC3 stably expressing LNCaP cell line and characterized the autophagic activity by western blot, translocation assay and Atg5 siRNA transfection. I also confirmed the autophagic activity in PC3.EGFP.LC3 cells. I was able to enrich autophagosomes using gradient ultracentrifugation and currently trying to optimize the condition for further purification by Immunopurification using beads.

## Subject Terms
- Autophagy
- Prostate cancer
- Subcellular Organelle Purification
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>8</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>8</td>
</tr>
<tr>
<td>Conclusion</td>
<td>8</td>
</tr>
<tr>
<td>References</td>
<td>8</td>
</tr>
<tr>
<td>Appendices</td>
<td>9</td>
</tr>
</tbody>
</table>
Introduction:

I, Ramesh Kaini, PI of the project (Title: Molecular Basis of Autophagic Cell Death, contract no.: W81XWH-08-1-0183); was awarded FY07 Prostate Cancer Training Award (Pre-doctoral -PhD) to pursue my career in prostate cancer research. The purpose of the award is to support me to understand the molecular basis of autophagy and its role in cell survival and cell death of prostate cancer cells in response to different stimuli. My focus is to isolate autophagosomes from both autophagic cell death and autophagic cell survival prostate cancer cell models and profile proteomes and lipidomes to identify novel autophagy abundant and/or specific protein and lipid molecules that are essential for functional autophagy in prostate cancer cells. The project consists of three aims: (i) to create autophagic cell death and autophagic cell survival models in LNCaP (P53+/+) and PC-3 (P53−) cells; (ii) to purify autophagy abundant and specific vacuoles, autophagosomes and autolysosome; and (iii) to profile and characterize membrane protein and lipid species of autophagosomes and autolysosome using quantitative proteomic and lipidomic approaches.

Body:

A. Training Accomplishments:

This year, I mainly focused to update my knowledge and expertise in cancer biology, autophagy and required techniques. Notable was my “The Edward A. Smuckler Memorial Workshop” award to attend the “AACR Workshop in Cancer Research: Pathobiology of Cancer” at Snowmass village, CO from July 6-13, 2008. The intense one week long workshop was very helpful for me to widen my knowledge in cancer pathogenesis at molecular and morphologic level from some of the best scientists working in the field. I also continued to actively participate in CMBD seminar, departmental journal club, pathology grand round and cancer center visiting professor lectureship. These seminars/journal club / grand rounds continue to help me to widen my knowledge in multiple disciplines of biomedical science. Besides, participation in regular prostate cancer interest group meeting was also productive for me to update with recent advances in prostate cancer research.

Throughout year, my mentor Dr. Andy Hu was very supportive in providing guidance and research support. He was always there when I need help. He was also very keen on helping me to develop professionalism. This year, he also provided me an opportunity to assist in peer-reviewing an article. It was a great experience for me to critically analyze a review paper and provide comments in a professional way. My co-mentor, Dr. Laurel Sillerud was also very supportive to guide me through the problems encountered during research. I have also regular interaction with other advisors, Dr. Bisoffi & Dr. Deretic.

This year, I learned and applied the techniques, gradient ultracentrifugation and confocal microscopy. I also learned the principle and sample preparation for electron microscopy and flow cytometry.

As of Fall 2008; I have earned 88 credit hours with cumulative GPA of 3.87.

B. Research Accomplishments:

There are three specific aims of my project as outlined previously in the introduction. The target was to achieve Specific Aim 1 and 2 in the first two years and Specific Aim 3 in the third year.
Accomplishments for Aim 1:

I successfully transfected the LNCaP cells with pEGFP.LC3 plasmid construct (gift from Dr. Noburu Mizushima) and generated stably transfected clone of LNCaP cells. Stably transfected cells were selected by continuously growing the transfected cells under G418 selective pressure (400 ug/ml). During autophagy, cytosolic EGFP.LC3 are processed and targeted to newly forming autophagosomes which are observed as distinct puncta under the fluorescence microscopy (1-2). I induced autophagy by incubating LNCaP.EGFP.LC3 cells in starvation medium and assessed autophagy by observing the translocation of diffused cytosolic recombinant EGFP.LC3 protein to distinct puncta (Fig. 1A,B). Autophagic activity was quantified by calculating the percentage of cells showing distinct puncta over different time points of starvation (Fig 1C). Similar results were observed in pEGFP.LC3 stably transfected PC3 prostate cancer cell line (obtained from Dr. wei-Pang Hwang).

Exogenously expressed EGFP.LC3 can sometime aggregate and show distinct puncta formation independent of autophagic activity (2,3). Atg5 is a key molecule required for the formation of autophagosomes(1-3). I did Atg5 siRNA transfection in EGFP.LC3 stably expressing LNCaP cells and observed that knocking down of Atg5 abrogated the translocation of cytosolic EGFP.LC3 to distinct puncta (fig 2). This confirmed that my EGFP.LC3 transfected cells are bonafide autophagic model.
Currently, I am working forward to characterize proposed autophagic cell survival model by using sulforaphane. ApoL1 induced autophagic cell death is defined in the attached two co-authored papers (Appendices 1, 2).

Accomplishments for Aim 2:

To establish the method for isolation and purification of autophagosomes from LNCaP-EGFP.LC3 cells and PC3-EGFP.LC3 cells induced by starvation in HBSS medium (pro-survival); I initially enriched the autophagic fraction by differential centrifugation. I biotinylated the antibodies against LC3 and conjugated with streptavidin coated magnetic beads. Then, the enriched autophagic fraction was incubated with Anti-LC3-Mag-Nap and the bound organelle fraction was washed three times. However, thus purified autophagosomes was not pure enough for downstream proteomic and lipidomic study on multiple repeated attempts.

As discussed earlier, the recombinant protein EGFP.LC3 translocates to autophagic membrane during autophagosomes formation. So, I used antibody against EGFP to selectively immunopurify autophagosomes, but the result was similar to that obtained by using antibody against LC3. Intracellular lysosomes have been purified using flow cytometry assisted organelle sorting (FAOS) (4). To take advantage of selective localization of EGFP.LC3 in the autophagosomes; I tried to sort out autophagosomes using flow cytometry assisted organelle sorting as an alternative method to
isolate autophagosomes. However, the signal was not enough to detect by the flow cytometry and that approach was aborted.

Another promising method to purify intracellular organelles is gradient ultracentrifugation. I tried to enrich autophagosomes by using sucrose gradient followed by immunopurification using antibodies tagged with magnetic particles. Previously, rat liver autophagosomes were also purified by using nycodenz/ percoll gradient (6). I attempted to imply the same methods to purify autophagosomes. Both methods work to highly enrich the autophagosomes.

I’m further trying to optimize the condition for Immunopurification of these purified autophagosomes from density gradient centrifugation, by using antibody against LC3 or EGFP that are conjugated with beads. I hope, immunopurification after the successful density gradient ultracentrifugation will yield enough pure autophagic samples for my downstream proteomic and lipidomic study. Based on contamination level, I plan to imply negative selection of contaminants before positive selection of autophagosomes using beads tagged with antibody against the molecular marker of contaminating organelles.
Key Research Accomplishments:

# Successfully established stably transfected LNCaP.EGFP.LC3 cells.

# Characterized and confirmed the autophagic activity in LNCaP.EGFP.LC3 cells by western blot, translocation assay and Atg5 siRNA transfection experiment.

# Confirmed autophagic activity in PC3.EGFP.LC3 cells.

# Co-authored and documented ApoL1 induced autophagic cell death model.

# Obtained purified autophagosomes from gradient ultracentrifugation.

Reportable Outcomes:

1. LNCaP.EGFP.LC3 cells.


Conclusion:

I completed the most part of Aim 1 and am currently trying to optimize the purification of autophagosomes using density gradient and immunopurification. I’m hopeful that I'll complete the remaining part on Aim 1 and Aim 2 before the completion of year 2 of funding as targeted.

I also widened my breadth of knowledge a lot on prostate cancer, cancer pathogenesis and other discipline of biomedical science through various workshops, didactic journal club/ seminars/ grand rounds and group meeting.

References:


**Appendices**
Apolipoprotein L1, a Novel Bcl-2 Homology Domain 3-only Lipid-binding Protein, Induces Autophagic Cell Death*

Guanghua Wan, Siqin Zhaorigetu, Zhihe Liu, Ramesh Kaini, Zeyu Jiang, and Chien-an A. Hu1

From the Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131

The Bcl-2 family proteins are important regulators of type I programmed cell death apoptosis; however, their role in autophagic cell death (AuCD) or type II programmed cell death is still largely unknown. Here we report the cloning and characterization of a novel Bcl-2 homology domain 3 (BH3)-only protein, apolipoprotein L1 (apoL1), that, when overexpressed and accumulated intracellularly, induces AuCD in cells as characterized by the increasing formation of autophagic vacuoles and activating the translocation of LC3-II from the cytosol to the autophagic vacuoles. Wortmannin and 3-methyladenine, inhibitors of class III phosphatidylinostol 3-kinase and, subsequently, autophagy, blocked apoL1-induced AuCD. In addition, apoL1 failed to induce AuCD in autophagy-deficient ATG5\(^{-/-}\) and ATG7\(^{-/-}\) mouse embryonic fibroblast cells, suggesting that apoL1-induced cell death is indeed autophagy-dependent. Furthermore, a BH3 domain deletion construct of apoL1 failed to induce AuCD, demonstrating that apoL1 is a bona fide BH3-only pro-death protein. Moreover, we showed that apoL1 is inducible by p53 in p53-induced cell death and is a lipid-binding protein with high affinity for phosphatidic acid (PA) and cardiolipin (CL). Previously, it has been shown that PA directly interacts with mammalian target of rapamycin and positively regulated the ability of mammalian target of rapamycin to activate downstream effectors. In addition, CL has been shown to activate mitochondria-mediated apoptosis. Sequestering of PA and CL with apoL1 may alter the homeostasis between survival and death leading to AuCD. To our knowledge, this is the first BH3-only protein with lipid binding activity that, when overproduced intracellularly, induces AuCD.

Bcl-2 family members play crucial roles in regulating programmed cell death (PCD).2 In stressed cells the live-or-die decision is largely determined by interplay between opposing members of the Bcl-2 protein family (1–4). Each member of the Bcl-2 family contains at least one of four conserved amino acid (aa) sequences, Bcl-2 homology (BH) domains 1–4. Based on their function in PCD, the Bcl-2 family members can be divided into three subgroups as follows: multi-BH domain anti-death, multi-BH domain pro-death, and BH3-only pro-death (1–3). The BH3 domain is conserved across all Bcl-2 family members and is the only domain retained by BH3-only proteins, further emphasizing the functional significance of this domain (4). In mammals, there are two major types of PCD, apoptosis and autophagic cell death (AuCD). Apoptosis (type 1) is characterized by nuclear condensation/DNA fragmentation and cell membrane alteration, without major ultrastructural changes of subcellular organelles. It usually involves the activation of caspases as well as the release of apoptogenic effectors, such as cytochrome c and apoptosis-inducing factor, from mitochondria that contribute to the acquisition of the apoptotic morphology (5–8). The molecular basis of AuCD (type 2), however, is not as well characterized in mammalian cells, even though many lines of evidence connect autophagy to human disease. Autophagy is generally defined as a lysosome-dependent mechanism of intracellular degradation that is used for the turnover of cytoplasmic constituents. There are three major classifications of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy (9–12). Macroautophagy (hereafter referred to as autophagy) is a highly conserved eukaryotic catabolic process involving the sequestration of the cargo (i.e. fraction of cytosol or organelles) within double membranes, creating autophagosomes, which then fuse with the endosome and lysosome to create autolysosomes. In the lumen of autolysosomes, lysosomal enzymes operate at low pH to catabolize the autophagic material (12–14). Autophagosomes and autolysosomes, also called autophagic vacuoles (AV), are considered to be de novo subcellular organelles specific to the autophagic process. Autophagy allows cells to eliminate large portions of the cytoplasm and is directly involved to eliminate aberrant protein aggregates, remove damaged/
aged organelles, defend against pathogen invasions, and cover an essential role in early neonatal development and differentiation (15–16). Upwards of 20 autophagy-related genes (ATG) have been identified, which regulate and/or directly participate in the autophagic pathway, particularly in AV formation (10, 13, 14). Deficiency of ATGs for example, ATG5 and ATG7, causes loss of AV formation and subsequently lack of autopha-
gic response. These deficiencies correlate with various dis-
ases such as cancer, cardiomyopathy, and neurodegenerative diseases (17–22). Paradoxically, recent evidence suggests that autophagy is, on the one hand, a survival pathway necessary to sustain mammalian viability during periods of starvation, and on the other hand, progressive autophagy can be a means to cell death (7, 11, 12). Significantly, Berry and Baehrecke (23) reported that autophagy is involved in physiological cell death during Drosophila development but is controlled by similar mechanisms as those that control autophagy function in cell survival. Furthermore, they provide in vivo evidence that both growth arrest and autophagy are required for physiological AuCD. However, the molecular determinants that dictate the control of autophagy for cell survival or death have not yet been revealed.

Aside from their role in apoptosis, the members of the Bcl-2 family also play an important role in autophagy. For example, when treating apoptosis-deficient cells, such as BAX and BAK double knock-out cells, with cytotoxic compounds (for example, etoposide), the primary response of those cells was AuCD, suggesting that homeostatic states of these knock-out Bcl-2 members play pivotal roles in regulating AuCD (24–27). In addition, it has been shown that the anti-death Bcl-2 and Bcl-xL can bind and inhibit Beclin1, a mammalian ortholog of yeast ATG6, and subsequently inhibit autophagy (28, 29). Overex-
pression of Beclin1 has been shown to induce formation of AV and autophagy in mammalian cells (28). Interestingly, Beclin1 has been found to be a haploinsufficient tumor suppressor fre-
quently mutated/deleted in breast, prostate, and ovarian can-
cers (12, 30, 31). Heterozygous knock-out mice of Beclin1 are tumor-prone, suggesting that the BH3 domain of Beclin1 mediates association with the suppression function (30). Importantly, structural and functional analyses showed that Beclin1 is a novel BH3-only protein, and this BH3 domain within Beclin1 mediates associ-
ations with Bcl-2 and Bcl-xL (32–34). In addition to Beclin1, recent studies showed other BH3-only members that also play regulatory roles in autophagy in physiological context. For example, Bid, a BH3-only protein, showed involvement in reg-
ulating both apoptosis and autophagy in breast cancer MCF-7 cells (35). Bad and BNIP3, two other BH3-only proteins, when overexpressed, can induce formation of AV in cancer cells (34, 36, 37). Interestingly, Bid, Bad, and BNIP3 are downstream tar-
gets of p53, a well characterized tumor suppressor and transac-
tivating factor. It has been shown that p53 plays a critical role in the suppression of tumorigenesis, in part, by the induction of both type I and type II PCD (38–41).

To identify and characterize novel BH3-only proteins in
AuCD and discover molecular regulators that dictate autoph-
gagy for death or survival, in this study, we utilized in silico data base-mining, functional expression, microscopy strategies, and lip binding assay to examine a novel BH3-only protein, apo-
lipoprotein L1 (apoL1).

**EXPERIMENTAL PROCEDURES**

**Cell Lines, Chemicals, and Culture Media**—DLD-1.TA14 (a p53-null, “Tet-Off” inducible colorectal cancer cell line) and Hec50co (a p53-null endometrial cancer cell line) and their cor-
responding growth medium and condition have been described previously (42–44). ATG5−/− and ATG7−/− mouse embryonic fibroblast (MEF) cells were gifts from Dr. Mizushima (15) and Dr. Komatsu (16), respectively. HEK293 and AD293 cell lines were purchased from ATCC and Clontech, respectively. All cell lines except DLD-1 were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum and 1% antimicro-
bial agents as described previously (44).

**Identification and Sequence Analysis of Novel BH3-only Proteins by Functional Genomics and Biocomputing Approaches**—The known BH3 domain consensus sequence and a data base-mining strategy were utilized to probe human genome and proteome data bases for the identification of novel BH3-only proteins as described previously (45). The annotated human open reading frames of candidate genes were down-
loaded from the most recent NCBI data base (build 36.2). In addi-
tion, candidate proteins were assessed for other putative domains/motifs, utilizing public sequence analysis programs and tools, such as the ExPASy proteomics server and ClustalW, as described previously (45). In addition, protein tertiary struc-
ture prediction was obtained from HMMSTR/ROSETTA (46, 47), and presentations of tertiary structure were made using Protein Data Bank files created with HMMSTR/ROSETTA and PyMOL.

**Cloning of Human ApoL1 cDNA and Generation of Inducible ApoL1 Gene**—Human apoL1 was identified as a putative BH3-
only protein by in silico data base mining. PCR was used to ampli-
fy the 1,194-bp full-length apoL1 cDNA. Subsequently, the sequence-confirmed apoL1 and apoL1 with a C-terminal FLAG tag (apoL1.FLAG) were cloned into pBI-EGFP vector (Clontech). The primers used for amplifying apoL1 were as fol-
loows: reverse, 5'-CCGCTTCAGTCAGCTTCTGGT-3' (bp +1,197 to +1,183), and forward, 5'-CGACGCGTATGG-
AGGGAGCTGCTTGTCG-3' (bp +1 to +19). The reverse primer used for amplifying apoL1.FLAG was 5'-CTAGCTAG-
CCTCATTAAGTTGTTAATCATGGGT-3' (bp +1,197 to +1,183). The resulting plasmids were used to transfect a previously described “Tet-Off” inducible sys-
tem in DLD-1.TA14 (44, 45). Stably transfected DLD-1 cells harboring pBI-apoL1 or pBI-apoL1.FLAG, namely DLD-
1-apoL1 and DLD-1-apoL1.FLAG, respectively, were selected in noninduction medium (D20) with 20 ng/ml doxycycline (Dox) as described previously (44, 45). We assayed inducible expres-
sion of apoL1 transcripts by semi-quantitative RT-PCR and immuno-
blot analysis.

**Site-specific Deletion Mutagenesis**—To generate the BH3 domain deletion allele of apoL1, that is to delete the 27 bp that encode the 9-amino acid BH3 domain (codons 158–166; base pairs +474 to +498), a PCR-based site-directed mutagenesis kit (ExSite, Stratagene) and the deletion-specific primers were used. Primer sequences were as follows: forward, 5'-AAGGTCC-
ApoL1, a Novel BH3-only Pro-death Protein, Induces Autophagy

AATAAGGCACCACG, and reverse, 5′-(p)CCTCCTATGTT-ATCCTACAGC. The deletion construct pBI-apoL1.dbH3 was confirmed by sequencing and was used to construct pAD-apoL1.dbH3 plasmid as described above (44).

ApoL1 Adenovirus (AD-ApoL1)—Construction, amplification, and assaying for titer of adenoviruses (AD) harboring apoL1 and apoL1.dbH3 alleles, and viral infection of mammalian cells were performed as described previously (44). A variety of cells were infected with control AD, AD-apoL1, and AD-apoL1.dbH3 with a range of concentrations from 0.01 to 5 multiplicity of infection (or plaque-forming units/cell, which was estimated to be 0.2–100 virus particles/cell) for 3 days. Cell numbers, cell death, and survival were measured over time by counting the attached cells, and by microscopy analysis in cell morphology (roundup) and increase of intracellular vacuole formation.

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37).
apoL1 (GenBank\textsuperscript{TM} accession number NM\_003661). We then retrieved full-length cDNA and protein sequences of apoL1 from the National Center for Biotechnology Information (NCBI) (ncbi.nih.gov) nucleotide and protein sequence data bases. Previously, using the same methodology, we reported the cloning and characterization of a \textit{bona fide} BH3-only pro-death gene apolipoprotein L6 (apoL6) and showed that overexpression of apoL6 induces mitochondria- and caspase 8-mediated apoptosis (45). Both apoL1 and apoL6 belong to a newly identified apolipoprotein L family that share significant sequence identity within the predicted amphipathic α-helix. Besides apoL1 and L6, apoL family has four other members, L2–5. It has been suggested that these proteins play important roles in lipid binding and transport (48–50).

Sequence analysis showed that apoL1 possesses a putative BH3 domain (aa 158–166) with 67% sequence identity with that of apoL6 (Fig. 1A). Over all, apoL1 and apoL6 possess 27% sequence identity and 42% similarity at the polypeptide level. In addition to the putative BH3 domain, apoL1 also possesses a leucine zipper domain (aa 365–392) (Fig. 1A). Sequence alignment of the 20-aa putative BH3 domain with a number of known BH3-only proteins (PUMA, BAD, NOXA, and apoL6) and apoL4, further showed that the 9-aa BH3 domain of apoL1 harbors the two important amino acids, Leu and Asp, conserved in all known BH3 domains (2, 4). By contrast, apoL4 does not possess the conserved Asp residue, which is substituted by an Asn instead (Fig. 1B). Tertiary structure prediction, of the 20-aa putative BH3 domain in the indicated proteins, showed that the 9-aa BH3 domains of known BH3-only proteins, PUMA, BAD, NOXA, and apoL6, show amphipathic α-helical structures. Importantly, the putative BH3 domain of apoL1 also possesses an α-helical domain. In contrast, apoL4 does not possess a complete, canonical α-helical structure in that region.

ApoL1 Induces Cell Death in a Variety of Cell Types—To investigate whether apoL1 induced cell death, we constructed a
**Figure 2.** Time- and dose-dependent induction of apoL1 and cell death in DLD-1.apoL1 cells. Induction of apoL1 expression is time-dependent as indicated by semi-quantitative RT-PCR using total RNA (A) or immunoblot analysis using total soluble proteins isolated from cells grown in induction medium (D.0) for the indicated time (B). C, apoL1 induces dose-dependent cell death. DLD-1.apoL1 cells were cultured in media containing Dox (D; ng/ml) as indicated. Attached cells were harvested and counted after 48 h. D, apoL1 induces time-dependent cell death. DLD-1.apoL1 cells were cultured in D.20 (Dox, 20 ng/ml) medium (squares) or D.0 (Dox, 0 ng/ml) medium (triangles), harvested, and counted at the times indicated. Each experiment was repeated at least three times. *, p < 0.05, indicates significant difference compared with control by Student’s t test.

**A.** ApoL1 and GAPDH expression in DLD-1.apoL1 cells after 0, 6, 12, 24, and 48 hr induction of apoL1 in D.20 medium (squares) or D.0 medium (triangles) harvested and counted at the times indicated.

**B.** ApoL1 and β-actin expression in DLD-1.apoL1 cells after 0, 6, 12, 24, and 48 hr induction of apoL1 in D.20 medium (squares) or D.0 medium (triangles) harvested and counted at the times indicated.

**C.** Cell number of DLD-1.apoL1 cells after 0, 6, 12, 24, and 48 hr induction of apoL1 in D.20 medium (squares) or D.0 medium (triangles) harvested and counted at the times indicated.

**D.** Cell number of DLD-1.apoL1 cells after 0, 6, 12, 24, and 48 hr induction of apoL1 in D.20 medium (squares) or D.0 medium (triangles) harvested and counted at the times indicated.

Tet-Off apoL1-inducible system in DLD-1 cells (DLD-1.apoL1) and adenovirus harboring wild type apoL1 (AD-apoL1) or a BH3 domain deletion construct of apoL1 (AD-apoL1.dBH3). We first examined whether apoL1 expression was inducible in a time-dependent manner in stably transfected DLD-1.apoL1 cells. Using semi-quantitative RT-PCR and total RNA isolated from DLD-1.apoL1 cells induced for 0, 6, 12, 24, and 48 h, we showed that there was time-dependent induction of apoL1 in induced DLD-1.apoL1 cells at the RNA level (Fig. 2A). We observed that expression of apoL1 was increased 3-4-fold 12 h after the removal of Dox (Fig. 2A). ApoL1 transcripts were also detectable in the DLD-1.TA14 control cells, thereby indicating that DLD-1 cells have some endogenous apoL1 expression (Fig. 2A). To confirm the induction of apoL1 expression at the protein level, we conducted immunoblot analysis on induced DLD-1.apoL1 cells using anti-apoL1 antibody. As shown in Fig. 2B, the amount of apoL1 protein was greatly increased (≥6-fold) 12 h after the induction. We then investigated whether overexpression of apoL1 could promote cell death. As shown in Fig. 2C, induction of apoL1 in DLD-1.apoL1 cells had a negative effect on cell proliferation significantly reducing the growth rate at 48 h when grown in the absence of Dox (D.0; Fig. 2, C, 4th column, and D). Dying/dead cells showed a change in cell morphology, increasing intracellular vacuoles, and detachment from culture plates. In contrast, DLD-1.apoL1 cells grown in D.20 exhibited normal growth (Fig. 2, C, 1st column, and D). Similar results were observed in DLD-1.apoL1.FLAG cells (data not shown). Because apoL1 expression was Tet-Off-regulated by the concentration of Dox in the culture medium, a cell growth study was conducted at various concentrations of Dox. In the presence of gradually increasing Dox concentrations, such as 1 ng/ml (D.1) and 5 ng/ml (D.5), cell death was decreased in DLD-1.apoL1 cells, implying that the cell death rate was related to the level of apoL1 expression. Furthermore, to investigate the importance of the BH3 domain of apoL1 in the induction of cell death, we constructed adenovirus harboring WT apoL1 (AD-apoL1) or a BH3 domain deletion mutant of apoL1 (AD-apoL1.dBH3) and used those to infect a variety of cell types, including HEK293 cells. As shown in Fig. 3A, cells overexpressing green fluorescence protein also overexpressed apoL1 protein. It is evident that greater than 95% of cells infected with AD-apoL1 were dead, same as those inducing DLD-1.apoL1 cells, 72 h after infection (Fig. 3A, panels b and e). In contrast, AD only or AD-apoL1.dBH3 failed to induce cell death (Fig. 3A, panels a and d, and c and f, respectively). Immunoblot analysis showed the protein products of WT apoL1 and apoL1.dBH3 were made in a time-dependent manner and were stable (Fig. 3B, 3rd and 6th lanes) for WT apoL1 and 4th and 7th lanes for apoL1.BH3. In addition, endogenous expression of apoL1 was very low in HEK293 cells with or without AD infection (Fig. 3B, 1st, 2nd, and 5th lanes). Identical results were observed for the same set of experiments in four different cell lines, DLD-1, HepG2 (liver cancer), MCF-7 (breast cancer), and LNCaP, PC3, and DU145 (prostate cancer) (data not shown). Thus, AD-apoL1 is a potent inducer of AuCD in a variety of cells and may be a general autophagy mediator.

**ApoL1 Induced Cell Death Is Not through Caspase-dependent Apoptosis**—Because apoL1 and apoL6 have high sequence and structure similarity and apoL6 induces caspase-dependent apoptosis, we examined whether apoL1-induced cell death was mediated through apoptosis. Fig. 4 showed that caspases 9 and 3 were not activated, and PARP, a well known substrate of caspases, was not cleaved during apoL1-induced cell death in DLD-1.apoL1 cells (Fig. 4A). By contrast, apoptotic DLD-1.apoL6 cells showed activation of caspase 9 8 h after apoL6 induction, which is consistent with previous findings (45).

**ApoL1 Induces Activation and Translocation of LC3-II**—To investigate whether apoL1-induced cell death acted through autophagy, we analyzed apoL1-induced activation and translocation of LC3-II to AV, a critical step in autophagic pathway. The amount of LC3-II has been shown previously to correlate with the number of AV (13, 14, 51). Immunoblot analysis of LC3 indicated a time-dependent accumulation of LC3-II and increase in the ratios of LC3-II to LC3-I in induced and aut-
ApoL1, a Novel BH3-only Pro-death Protein, Induces Autophagy

FIGURE 3. BH3 domain deletion construct of apoL1 failed to induce cell death in DLD-1 cells. A, adenoviruses harboring WT apoL1 (AD-apoL1) and BH3 domain deletion mutant of apoL1 (AD-apoL1.dBH3) were constructed and used to infect DLD-1 cells. Cells overexpressing green fluorescence protein also overexpressed apoL1 protein. AD-apoL1 induced cell death 72 h after infection (panels b (bright field) and e). In contrast, AD only or AD-apoL1.dBH3 failed to induce cell death (panels a (bright field) and d, and c (bright field) and f, respectively). B, time-dependent protein production of WT apoL1 and apoL1.dBH3. Hours after infection were as indicated. Note that endogenous expression of apoL1 was very low, almost undetectable, in DLD-1.apoL1 cells cultured in induction medium for 24 h. At least 300 DLD-1.apoL1 cells were analyzed for each experiment. Panel a, DLD-1.apoL1 cells cultured in normal medium, and panel b, DLD-1.apoL1 cells cultured in induction medium for 24 h, respectively. Induced DLD-1.apoL1 cells were deformed and slightly rounded. Panel c, panel a, and panel b, respectively. Induced DLD-1.apoL1 cells were deformed and slightly rounded.

FIGURE 4. ApoL1-induced cell death is through autophagy, not by apoptosis. A, caspases 9 and 3 were not activated, and PARP was not cleaved during apoL1-induced cell death. By contrast, apoL6 induces cell death through apoptosis by activation of caspases 9 as described previously (45). B, apoL1 induced activation and translocation of LC3. Immunoblot analysis of LC3 in autophagic DLD-1.apoL1 cells. Total soluble proteins were isolated at indicated time points from DLD-1.apoL1 cells cultured in induction medium. Times after induction of apoL1 are as indicated. Accumulation of LC3-II in induced DLD-1.apoL1 cells can be seen 12 h after induction. The ratios between LC3-II and LC3-I were 0.1, 2, and 20:0.1, 12, and 24 h after induction, respectively. C, immunofluorescence staining of LC3 (red) in DLD-1.apoL1 cells. Panel a, DLD-1.apoL1 cells cultured in normal medium, and panel b, DLD-1.apoL1 cells cultured in induction medium for 24 h. At least 300 cells were analyzed for each experiment.

FIGURE 5. ApoL1 induces accumulation of AV and autophagic cell death, which can be inhibited by 3-MA and wortmannin. A, effect of 3-MA (5 mM) and wortmannin (1 μg/ml) on apoL1-induced cell death was observed by light microscopy analysis. 3-MA and wortmannin were added to noninduction medium 8 h prior to the induction of apoL1. Panel a, DLD-1.apoL1 cells in noninduction (regular) medium; panel b, in induction medium; panel c, in induction medium + 3-MA; and panel d, in induction medium + wortmannin. Obviously, 3-MA and wortmannin partially blunt apoL1-induced cell death in DLD-1.apoL1 cells by 55 and 40%, respectively. All the images were taken by the same inverted microscope (Olympus, CK40) with a MacroFire digital camera (OPTRONIC, model S99831). B, electron microscopy analysis of autophagic DLD-1.apoL1 cells. Panel a, control DLD-1.apoL1 cells; panels b and c, autophagic DLD-1.apoL1 cells under two different magnifications; panels d–f, magnified views of vacuoles in the cell shown in panel c. Panel d, an enlarged empty vacuole; panel e, a double-membraned structure presumably an autophagosome; panel f, an AV, presumably an autolysosome, engulfing an electron-dense body. Scale bars are as indicated. Data are representative of four experiments. Each experiment was repeated at least three times.

ApoL1 induces increased formation of AV and autophagy—which can be inhibited by 3-MA and wortmannin—transmission electron microscopy (TEM) is one of the most sensitive and definitive methods to detect autophagic compartments in mammalian cells (52, 53). To further confirm that apoL1-induced cell death was indeed through autophagy, we conducted both light microscopy and TEM analyses. Normal DLD-1.apoL1 cells under light microscopy and TEM were displayed in Fig. 5, A, panel a, and B, panel a, respectively. Induced DLD-1.apoL1 cells with increased expression of apoL1 showed significant formation of AV under the TEM (Fig. 5B, panels b and c). The magnified images showed an enlarged empty vacuole (Fig. 5B, panel d), a double-membraned AV (Fig. 5B, panel e), and an autophagosome engulfing an electron-dense body (Fig. 5B, panel f) in an induced DLD-1.apoL1 cell (Fig. 5B, panel c). Induced DLD-1.apoL1 cells were deformed and slightly rounded.
ApoL1, a Novel BH3-only Pro-death Protein, Induces Autophagy

**Fig. 6.** ApoL1 fails to induce cell death in autophagy-deficient ATG5-/- and ATG7-/- MEFs. Wild type (WT), ATG5-/-, and ATG7-/- MEF cells were grown in Dulbecco’s modified Eagle’s medium to 30% confluence, infected with control AD or AD-apoL1 viruses for 36 h, and followed by light microscopy analysis (A). Greater than 90% of WT MEF cells infected with AD-apoL1 had died, whereas less than 20% of the ATG5-/- or ATG7-/- (not shown) cells were dead. B, immunoblot analysis showed overexpression of apoL1 protein was achieved at 36 h after infection of AD-apoL1 in ATG5-/-, WT, and ATG7-/- MEFs. Importantly, apoL1 again induced activation of LC3 II and increased the ratio of LC3-II to LC3-I in WT MEF cells (Fig. 6A). By contrast, apoL1 failed to induce activation of LC3 in the ATG5-/- and ATG7-/- cells. Of note, it has been reported that MEFs have high endogenous LC3-II (15, 16).

ApoL1 Fails to Induce Cell Death in Autophagy-deficient MEFs—To further confirm apoL1 induces AuCD, two inhibitors of autophagy, 3-MA and wortmannin, were used. It has been well documented that MEFs have high endogenous LC3-II (15, 16). Thus, cells lacking either ATG5 or ATG7 are defective in LC3-II activation and autophagosome formation. MEF cells were infected with AD-apoL1 for 36 h at which point induction of apoL1, cell death, and LC3 activation were assayed. Fig. 6A showed that greater than 90% of WT MEF cells infected with AD-apoL1 had died, whereas less than 20% of the ATG5-/- cells were dead. Fig. 6B showed overexpression of apoL1 protein was achieved at 36 h after infection of AD-apoL1 in ATG5-/-, ATG7-/-, and WT MEFs. Importantly, apoL1 again induced activation of LC3 II and increased the ratio of LC3-II to LC3-I in WT MEF cells (Fig. 6B). By contrast, apoL1 failed to induce activation of LC3 and autophagy, as expected, in both the ATG5-/- and ATG7-/- cells. These results further indicate that apoL1-induced cell death is autophagy-dependent.

Expression of ApoL1 Is Up-regulated by P53 in P53-induced Cell Death—Previous studies showed that p53, one of the master regulators in PCD, induces both apoptosis and autophagy (39, 40). To investigate whether the expression of apoL1 was regulated by p53, we took advantage of two of our previously used cancer cell models, DLD-1.p53 and Hec50co, in p53-induced apoptosis. Overexpression of p53 was achieved in DLD-1.p53 cells by Tet-Off induction and in Hec50co cells by AD-p53 infection as described previously (44). Immunoblot analysis showed time-dependent expression of apoL1 under the influence of p53 in both cell lines. As shown in Fig. 7, induction of apoL1 was detected 8 and 12 h after p53 overexpression in DLD-1.p53 cells and Hec50co cells, respectively, and 16 and 12 h prior to p53-induced cell death in DLD-1.p53 cells and Hec50co cells, respectively. This indicates that apoL1 is inducible by p53 during p53-induced cell death.

ApoL1 Binds Strongly with PA and CL and Less with Some Phosphoinositides—To explore the binding of apoL1 to lipids, apoL1.FLAG showed strong binding affinity for PA and CL but...
ApoL1, a Novel BH3-only Pro-death Protein, Induces Autophagy

FIGURE 8. Interacting lipid species of apoL1.FLAG protein. Affinity-purified apoL1.FLAG fusion protein was used to conduct lipid overlay assay (see “Experimental Procedures” for details). A, purified apoL1.FLAG was confirmed by immunoblot analysis using both anti-apoL1 and anti-FLAG antibodies. B, apoL1.FLAG bound strongly with CL and PA, followed by PI-3,5-P2, PI4P, PI3,5P2, PI3,4,5-P3, 3-sulfogalactosylceramide (3-SGCer), phosphoserine, PE, and PI (very weak). ApoL1.FLAG did not bind cholesterol (CHO), TG, PE, PC, SM, diacylglycerol (DAG), or sphingosine 1-phosphate, lysophosphatidic acid (LPA), and lysophosphatidylethanolamine (LPE). Lipid abbreviations are as follows: TG (triglyceride), PI (phosphatidylinositol), DAG (diacylglycerol), PI4P (PtdIns(4)P), PA (phosphatidic acid), PI4,5P2 (PtdIns(4,5)P2), PS (phosphatidylserine), PI3,4,5P3 (PtdIns(3,4,5)P3), PE (phosphatidylethanolamine), CHO (cholesterol), PC (phosphatidylinositol), SM (sphingomyelin), PG (phosphatidylglycerol), 3-SGCer (3-sulfogalactosylceramide (Sulfatide)), CL (cardiolipin), S1P (sphingosine 1-phosphate), LPA (lysophosphatidic acid), LPC (lysophosphocholine), PI3,4P3 (PtdIns(3,4)P3), PI3,5P2 (PtdIns(3,5)P2), PI3P (PtdIns(3)P), PI4P (PtdIns(4)P), PI4P (PtdIns(4)P), and Solvent blank (Blank).

less affinity with different species of PIPs and other phospholipids in the following order: phosphatidylinositol 3,5-bisphosphate (PI-3,5-P2) > PI4P > PI5P > PI3P > PI-4,5-P2 > PI-3,4,5-P3 > PI-3,4-P2 > 3-sulfogalactosylceramide > phosphoserine > phosphoglycerol (PG) > phosphoinositol (PI) (Fig. 8B). Interestingly, apoL1 did not bind cholesterol, phosphoethanolamine (PE), phosphocholine (PC), sphingomyelin (SM), triglyceride (TG), diacylglycerol, sphingosine 1-phosphate, lysophosphatidic acid, and lysophosphocholine.

DISCUSSION

The role of the Bcl-2 family in regulating apoptosis is well studied; however, its role in mediating AuCD is still elusive. In an effort to identify and characterize novel BH3-only proteins in AuCD, we identified a novel BH3-only pro-death protein apolipoprotein L1 (apoL1) in silico. Subsequently we showed that WT apoL1 induces AuCD in a variety of cells, whereas the BH3 deletion construct of apoL1 failed to induce cell death. Interestingly, apoL1 protein has been found both inside the cells and circulating in the blood. When it is in the serum, apoL1 binds apolipoprotein A-I and is one of the components of high density lipoprotein (HDL) particles, suggesting apoL1 has a role in lipid metabolism (48, 49). In addition, protein secondary structure analysis identified four lipid-binding amphipathic α-helices in apoL1, which may function as a catalyst for intra- and extracellular lipid transfer (48–50). Importantly, we previously reported that apoL6, a closely related protein of apoL1 and a BH3-only pro-death protein, induces mitochondria- and caspase-mediated apoptosis (45). By contrast we showed apoL4, another member of the apoL family not possessing BH3 domain, failed to induce cell death. Sequence analysis showed that six of the nine residues of the BH3 domain are identical between apoL1 and apoL6 (Fig. 1A). In addition, the BH3 domain of apoL1 showed an amphipathic α-helical structure similar to other known BH3 domains, including that of apoL6. Taken together, our results indicated that both apoL1 and apoL6 are bona fide BH3-only pro-death proteins. ApoL1 and apoL6 possess conserved primary sequence and tertiary structure; nevertheless, they function differently and nonredundantly in the induction of PCD. ApoL6 induces apoptosis (type I), whereas apoL1 induces autophagy (type II). It is not unreasonable to postulate that their interacting partners, protein and/or lipid species, play important role in mediating different death-signaling pathways. As a matter of fact, we showed that apoL1 has very strong affinity for PA and CL. CL is a dimer of PG and PA and includes four acyl chains, two phosphate groups, and three glycerols. As apoL1 binds strongly with PA, it is logical to speculate that apoL1 binds CL through its PA moiety. Interestingly, Fang et al. (55) previously showed that PA is a critical component of mammalian target of rapamycin (mTOR) signaling. They showed mitogenic stimulation of mammalian cells led to a phospholipase D-dependent accumulation of cellular PA, which was required for activation of mTOR downstream effectors. PA directly interacted with the domain in mTOR that is targeted by rapamycin, and this interaction was positively correlated with the ability of mTOR to activate downstream effectors. It has also been shown that mTOR is a negative regulator of autophagy (40, 56). Thus, binding of PA by apoL1 might inhibit mTOR activation and subsequently induce autophagy. In addition, accumulating evidence suggests that CL has active roles in mitochondria-mediated apoptosis (57). Binding of CL with apoL1 may prevent apoptosis in favor of induction of AuCD. PIPs play critical roles in regulating cellular signaling pathways. The homeostatic equilibrium of PIPs determines cellular proliferation, differentiation, trafficking, and PCD (58, 59). It has been shown that PI4P is the most abundant member of...
ApoL1, a Novel BH3-only Pro-death Protein, Induces Autophagy

PIPs. Furthermore, PI-3,4,5-P₃ and PI-3,4-P₂ can induce cell growth through the Akt pathway, but PI3P has been shown to induce autophagy and endosomal trafficking. Our results showed that binding of apoL1 to various species of PIPs may alter the homeostasis of PIPs leading to the AuCD. Interestingly, we found that apoL1 did not bind cholesterol, TG, PC, PE, or SM, the major lipid components in HDL (Fig. 8B). It has been shown that apoL1, a minor protein component, can directly interact with apoAI, the major protein component in HDL (48). It is logical to postulate that apoL1, which does not interact with HDL lipid species, binds and modulates the activities of apoAI. To our best knowledge, apoL1 is the first BH3-only, lipid-binding apolipoprotein that induces AuCD.

Interestingly, the genes encoding apoLs are localized to chromosome 22q12.3-13.1, a high susceptibility locus for schizophrenia. Importantly, expression of apoL1 has been shown to be significantly up-regulated (≥1.41-fold) in the brains of schizophrenics (60). It will be interesting to see whether overexpression of apoL1 induces AuCD in central nervous system cells, and if so what role of apoL1 plays in the etiology of schizophrenia.

ApoL1 was recently found to be the trypanosome lytic factor in human serum. The parasite Trypanosoma brucei rhodesiense causes human sleeping sickness in Africa. The molecular basis of this disease is the product of resistance-associated protein, an inhibitory protein that binds specifically to apoL1 to prevent cell lysis. Unchaperoned apoL1 promotes forming anion channels on lysosomal membranes of trypanosome and subsequently kills the parasite (61, 62). Thus, in addition to the aforementioned functions, apoL1 can also play an important role in innate immunity.

It is well documented that LC3 is required for complete autophagosome formation during autophagic pathway in mammalian cells. The combination of alteration of subcellular localization of LC3-II with increased ratio of LC3-II to LC3-I is one of the hallmarks of autophagy (13, 14). This study demonstrates that apoL1 is a potent and specific inducer of AuCD that stimulates time-dependent accumulation and translocation of LC3-II, formation of the AV (confirmed by TEM analysis), and subsequently cell death in apoL1-overexpressing cells. Importantly, no apoptotic hallmarks, such as release of apoptogenic factors from mitochondria or activation of caspases, were detected in apoL1-induced cell death. We also showed that expression of apoL1 is inducible by p53, a well known tumor suppressor and transactivating factor frequently mutated in cancers, which regulates both types of PCD (38–41). Regarding the role of p53 in autophagy, it has been shown that direct activation of p53 by nutrient starvation and serum deprivation induces autophagy in cancer cells (40). In addition, damage-regulated autophagy modulator, a p53 target gene encoding a lysosomal protein, has been shown to be involved in the induction of autophagy (63). Furthermore, Bad and Bid, two BH3-only proteins and direct downstream effectors of p53, not only play important roles in apoptosis but also in autophagy (34, 36, 37). Our results suggest that apoL1 is a novel BH3 only protein and is a p53 downstream effector functioning as a molecular determinant that dictates autophagy for death (Fig. 9).

Regarding other BH3-only proteins in PCD, Beclin1 interacts with anti-apoptotic Bcl-2 by virtue of its BH3 domain, an amphipathic α-helix, that binds to the hydrophobic cleft of Bcl-2. Interestingly, the association of Beclin1 with Bcl-2 is of low affinity (1–2 μM) as compared with other BH3-only proteins that bind to Bcl-2 (in low nanomolar range) (32–34). In fact, it has been shown that Bad, as well as BH3-mimetic compounds such as ABT737, competitively disrupt the inhibitory interaction between Beclin1 and Bcl-2 (34). Thus, it is logical to speculate that when the other BH3-only proteins, such as apoL1 and apoL6, are induced by various stimuli/stresses, they can displace Beclin1, rendering the cell susceptible to autophagy as well as apoptosis, respectively. It will be of interest to investigate whether apoL1 and apoL6 interact with anti-death Bcl-2 family members and the functional consequences of the interactions in PCD. Finally, apoL1 provides an excellent model to further study the molecular basis of gene-induced AuCD.

Acknowledgments—We thank Dr. Steven Jett and Tamara Howard for their excellent EM service at the EM Core Facility, University of New Mexico School of Medicine.

REFERENCES


FIGURE 9. Hypothetical model of apoL1-induced autophagic death in cancer cells. Expression of apoL1 is inducible by p53, a tumor suppressor gene. Intracellular accumulation of apoL1 alters lipid homeostasis and signaling, induces activation and translocation of LC3, and generation of autophagic vacuoles leading to cell death. Inhibitors of autophagy, such as 3-MA or wortmannin, blunt apoL1-induced autophagic cell death.

Downloaded from www.jbc.org at UNIV OF NEW MEXICO on March 28, 2009
Apol1, a Novel BH3-only Pro-death Protein, Induces Autophagy


Bystroff, C., and Shao, Y. (2002) Bioinformatics (Oxf) 18, 554–561


Estelkine, E.-L. (2005) Autophagy 1, 1–10


ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death

Siqin Zhaorigetu, Guanghua Wan, Ramesh Kaini, Zeyu Jiang, and Chien-an A. Hu*

Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, School of Medicine, Albuquerque, NM 87131, USA

Abstract

We recently reported the identification and characterization of a novel BH3-only pro-death protein, apolipoprotein L1 (ApoL1), that, when overexpressed, induces autophagic cell death (ACD) in a variety of cells, including those originated from normal and cancerous tissues. ApoL1 failed to induce ACD in autophagy-deficient Atg5−/− and Atg7−/− MEF cells, suggesting that ApoL1-induced cell death is indeed autophagy-dependent. In addition, a BH3 domain deletion allele of ApoL1 was unable to induce ACD, demonstrating that ApoL1 is a bona fide BH3-only pro-death protein. To further investigate regulation of ApoL1 expression, we showed that ApoL1 is inducible by interferon-γ and tumor necrosis factor-α in human umbilical vein endothelial cells, suggesting that ApoL1 may play a role in cytokine-induced inflammatory response. Moreover, we observed that ApoL1 is a lipid-binding protein with high affinity for phosphatidic acid and cardiolipin and less affinity for various phosphoinositides. Functional genomics analysis identified 5 nonsynonymous single nucleotide polymorphisms (NSNPs) in the coding exons of the human ApoL1 structural gene— all the 5 NSNPs may cause deleterious alteration of ApoL1 activity. Finally, we discuss the link between ApoL1 and various human diseases.

Keywords

trypanosomal lytic factor; apolipoprotein L1 (ApoL1); autophagy; autophagic cell death; BH3-only protein; cardiolipin; lipid binding; PIPs; phosphatidic acid; schizophrenia; SNPs
physiological cell death during development of *Drosophila* and *Dictyostelium discoideum*, however, ACD has not yet been observed/demonstrated in mammals *in vivo*.\(^5,6\)

In the past two decades, yeast has been used as an experimental model in dissecting the molecular bases of autophagy. Currently 31 ATG (autophagy-related) genes have been identified in yeast.\(^3,6\) Recent identification and characterization of human orthologs/homologs of yeast ATG genes and the link between autophagy and human diseases further emphasize the importance of autophagy in health and disease. Deficiency of autophagy correlates with diseases such as cancer, cardiomyopathies, inflammatory bowel diseases and neurodegenerative diseases.\(^5,7\) In addition, autophagy involves unique membrane dynamics and biosynthesis, requiring *de novo* synthesis of double-membrane autophagosomes, in which both protein and lipid components are required. Regarding protein components, aside from Atg proteins, Vps34, a class III phosphatidylinositol-3-phosphate kinase (PI3K), the proteins that are part of its complex, and the Bcl-2 family members play critical roles in regulating autophagosome formation. Interestingly, Beclin 1, the mammalian ortholog of yeast Atg6 that is required for autophagy, is a BH3-only protein. In addition, other Bcl-2 family members, such as Bcl-2, Bax, Bid and BNIP3, regulate autophagy.\(^6,8\) By contrast, the lipid composition of autophagosomal membranes remains unknown because it is technically difficult to isolate pure autophagosomes. It is evident however that some lipid species, for example, phosphatidylinositol-3-phosphate or PI3P, are required for autophagosomal membranes.\(^1,9\)

In an effort to identify and characterize novel BH3-only proteins in ACD, and discover molecular regulators that dictate autophagy for death or survival, we examined a novel BH3-only protein, apolipoprotein L1 (ApoL1). We show that wild-type ApoL1 induces ACD in a variety of cells, whereas a BH3 deletion allele of ApoL1 fails to induce cell death, indicating that ApoL1 is a *bona fide* BH3-only pro-death protein. We further demonstrate that ApoL1 is a potent and specific inducer of ACD that stimulates time-dependent accumulation and translocation of lipidated LC3-II, formation of autophagosomes and subsequently cell death. We also show that ApoL1 is inducible by p53 during p53-induced cell death. p53, a well-known tumor suppressor, regulates both apoptosis and ACD.\(^4\) Interestingly, a recent study shows that p53 plays a dual role in the control of autophagy: on the one hand, nuclear p53 can induce autophagy through transcriptional effects, whereas on the other hand, cytoplasmic p53 may act as a master repressor of autophagy.\(^10\) Our results suggest that ApoL1 is a novel BH3-only protein and is a p53 downstream effector functioning as a molecular determinant that determines whether autophagy plays a role in cell death.\(^4\) Importantly, ApoL1 has been found only in humans and African green monkeys (NCBI Entrez Gene, ApoL1), suggesting that ApoL1-induced ACD is primate-specific.

Employing a protein-lipid overlay assay, we demonstrate that ApoL1 is an intracellular lipid-binding protein that binds strongly with phosphatidic acid (PA) and cardiolipin (CL), and with less affinity with different species of phosphoinositides (PIPs) in the following order PI(3,5)P\(_2\)>PI(4,5)P\(_2\)>PI(4,5)P\(_2\)>PI(4,5)P\(_2\)>PI(3,4,5)P\(_2\)>PI(3,4)P\(_2\).\(^4\) PIPs are phosphorylated derivatives of the membrane phospholipids phosphatidylinositols and play critical roles in regulating receptor signaling, cytoskeleton function and membrane trafficking. They are highly concentrated and localized in distinct pools in the plasma membrane, endosomes, nucleus and autophagosomal membranes, where they function as ligands, adaptors or docking sites for PIP-binding proteins. In addition, the homeostatic equilibrium of PIPs determines cellular proliferation, differentiation and PCD.\(^11,12\) Vps34 is required for autophagy, implying an essential role of its product PI3P in this process.\(^13\) Recently, Obara and colleagues\(^9\) showed that PI3P is highly enriched and delivered to autophagosomal membranes but not as a cargo enclosed in autophagosomes, implying direct involvement of PI3P in autophagosome formation. They also report a possible enrichment of PI3P on the inner autophagosomal membranes compared to the outer membrane.\(^9\) Regarding binding with PIPs, we show that
ApoL1 possesses higher affinity for PIP(3,5)P$_2$, PI4P, PI5P, and PI3P, implying that intracellular accumulation of ApoL1 may alter the homeostasis of PIPs leading to ACD. In addition, we conducted a protein domain homology search and found no homology between ApoL1 and any known PIP-binding domains, including FYVE (Fab1, YOTB, Vac1 and EEA1), PX (Phox homology), PH (Pleckstrin homology), ENTH (Epsin N-terminal homology), FERM (Band4.1, Ezrin, Radixin, and Moesin), GRAM (Glucosyltransferase, Rab-like GTPase Activator, and Myotubularins), ANTH (AP180/CALM), and WD-repeats of WIP1s, human orthologs of yeast Atg18 and/or Atg20. In fact, no specific binding domain for PIP(3,5)P$_2$ has been identified thus far. Taken together, ApoL1 may represent a novel class of PIP-binding protein. Importantly, in autophagy, at least 2 Atg proteins are involved in PIP synthesis (Atg6 and Atg14) and 5 Atg proteins bind PIP (Atg18, Atg20, Atg21, Atg24 and Atg27). Evidently, yeast mutants deficient in PIP binding will be useful for functional complementation and biochemical analysis of human ApoL1.

Interestingly, ApoL1 also binds PA and CL. PA is a mitogenic messenger that serves as a critical component of mTOR signaling. PA directly interacts with the domain in mTOR that is targeted by rapamycin, and this interaction positively correlates with mTOR’s ability to activate downstream effectors. mTOR is a negative regulator of autophagy; thus, binding of PA by ApoL1 might inhibit mTOR activation and subsequently induce autophagy. In addition, CL, a negatively charged phospholipid abundant in the mitochondrial inner membrane, is important in maintaining protein (for example cytochrome c) and membrane integrity of mitochondria. During apoptosis, CL functions as the docking site for t-Bid and Bad and induces mitochondrial membrane permeability and cytochrome c release. In addition, CL relocates to the plasma membrane and other subcellular organelles during cell death. Sequestering of PA and CL with ApoL1 may alter the homeostasis between survival and death leading to ACD. To our knowledge, this is the first BH3-only protein with lipid binding activity that, when overproduced intracellularly, induces ACD.

Roles of ApoL1 in human diseases

African Sleeping sickness

The parasites *Trypanosoma brucei rhodesiense* and *Trypanosoma brucei gambiense* cause human sleeping sickness in Africa. It has been known for over a century that human serum contains trypanosomal lytic factor (TLF) that can lyse most of the invading trypanosome species. TLF, residing in a minor subclass of human high-density lipoprotein particles, contains apolipoprotein A-I (ApoA-I) and two primate-specific proteins, ApoL1 and hepatoglobin-related protein (Hrp), both of which are toxic to trypanosomes. The molecular basis of this disease is that pathological trypanosomes produce the serum resistance-associated protein (SRA), an inhibitory protein that binds specifically to ApoL1 to prevent trypanosomal lysis. Unsequestered and engulfed ApoL1 promotes the formation of anion (Cl$^-$) channels on lysosomal membranes of trypanosomes and induces osmotic swelling of lysosomes due to massive influx of chloride ions from the cytoplasmic compartment, and subsequently kills the parasite. In addition to ApoL1 and Hrp, Wildener and colleagues recently provided in vitro evidence that hemoglobin is a cofactor of human TLF that increases the affinity of TLF for its receptor, and therefore the internalization efficiency of TLF to the parasite. More importantly, ApoL1 alone is sufficient to confer trypanolytic activity in transgenic mice but both ApoL1 and Hrp are required to increase the specific activity of TLF. It is worth noting that a recent case report documents that an Indian patient whose serum lacked trypanolytic activity due to the absence of ApoL1 was infected by a serum-sensitive *T. evansi*, a strain that would normally not infect humans. Mutation analysis shows that the patient possesses two frameshift mutations in both ApoL1 alleles, further emphasizing the critical role of ApoL1 in innate immunity against trypanosomal infection. Nevertheless, it is evident that ApoL1-
induced cell death in mammalian cells is through autophagy, not through Cl\textsuperscript{−} influx and osmotic swelling of the lysosome that happens in trypanosomes and in \textit{E. coli}\textsuperscript{22,25} Our recent result showed that ApoL1 is localized in the cytosol, not in lysosomes, in mammalian cells (Wan et al., unpublished observation). In addition, ApoL1-induced trypanosomal lysis can be delayed by the anion blocker DIDS (4,4-diisothiocyanatostilbene-2,2-disulfonic acid). It is thought that ApoL1-mediated influx of Cl\textsuperscript{−} from the cytoplasm to the lysosome causes a change in the cytosolic Cl\textsuperscript{−} concentration that in turn causes a compensatory movement of extracellular Cl\textsuperscript{−} across the plasma membrane through DIDS-sensitive channels in trypanosomes.\textsuperscript{21} However, our recent observation indicated that DIDS fails to delay or block ApoL1-induced ACD in mammalian cells (Wan, unpublished observation). As indicated earlier, ApoL1 has been found only in humans and African green monkeys, suggesting that ApoL1-induced ACD is primate specific.

**Schizophrenia**

The human gene encoding ApoL1 is localized to chromosome 22q13.1, a region with loci that might be linked to susceptibility of schizophrenia. Importantly, expression of ApoL1 is significantly upregulated (>1.41 fold) in the brains of schizophrenics.\textsuperscript{26} Takahashi and colleagues\textsuperscript{27} recently performed a family-based association study using 377 families with schizophrenia and 130 SNPs (single nucleotide polymorphisms) associated with the ApoL gene family. They show that seven SNPs have p-values <0.05 in the ApoL1, ApoL2 and ApoL4 regions in 226 families (approximately 60%), suggesting ApoL genes should be more extensively studied in schizophrenia. It will be interesting to see whether overexpression of ApoL1 induces ACD in CNS cells, and if so, what role ApoL1 plays in the etiology of schizophrenia.

**Inflammation in atherosclerosis**

Atherosclerosis is a chronic inflammatory disease of the vasculature with lesions developing in the arterial wall, and it is governed by a complex network of inter- and intra-cellular signaling pathways. The pleiotropic, pro-inflammatory cytokine interferon-\(\gamma\) (INF-\(\gamma\)) and tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)) are key mediators that are highly expressed in atherosclerotic lesions.\textsuperscript{28} The endothelium, the monolayer covering the inner surface of blood vessels, plays a pivotal role in the regulation of vascular tone and structure, as well as vascular inflammation. Dysfunction of endothelial cells is an early sign of atherosclerosis. Interestingly, previous studies show ApoL1 is strongly induced by IFN-\(\gamma\) and TNF-\(\alpha\) in endothelial cells at the mRNA level.\textsuperscript{29} Using human umbilical vein endothelial cells (HUVEC), a model for endothelial cell physiology and pathophysiology, we recently showed that expression of ApoL1 at the protein level was significantly increased 6 h and 12 h after INF-\(\gamma\) and TNF-\(\alpha\) treatment, respectively (Figure 1), suggesting that ApoL1 plays a role in inflammatory and cell death response in endothelial cells. It would be of interest to investigate whether expression of ApoL1 is upregulated in human atherosclerotic tissues, and if so, how and why.

Regarding other possible roles of ApoL1 in human disease, in a microarray study Kang and colleagues\textsuperscript{30} show that ApoL1 is one of the senescence-associated genes that are induced greater than 14-fold in normal human oral keratinocytes undergoing senescence. However, the function of ApoL1 in aging/senescence has not been further explored. To explore possible genetic alterations in ApoL1 that may correlate with human disease, we conducted a SNP analysis by searching/mining the NCBI SNP database. We found NSSNPs, G96R, E150K, M228I, R255K, and D337N, in the coding sequence of human ApoL1 that alter amino acid sequences (Figure 2). All 5 of these changes are considered to be drastic. It is not unreasonable to postulate that some of these NSSNPs may be associated with human disease state. Future investigation of ApoL1 will focus on its disease association and lipid binding. For example,
whether the BH3 domain of ApoL1 is necessary for lipid binding, and whether binding of
different lipid species by ApoL1 is essential for the induction of ACD. Finally, ApoL1-induced
ACD provides an excellent model to dissect the molecular basis of autophagy and other
molecular determinants, both protein and lipid species, that dictate the control of autophagy
for cell survival or death.

Acknowledgements

This work was supported in part by NCI RO1 (5RO1CA106644-01A1) and to C.-A. A. Hu, and by DOD PCRP
predoctoral fellowship (W81XWH-08-1-0183) to R. Kaini.

Abbreviations

ANTH, AP180/CALM
ACD, autophagic cell death
AV, autophagic vacuoles
BH, Bcl-2 homology domain
CL, cardiolipin
ENTH, epsin N-terminal homology
FERM, band4.1, ezrin, radixin, and moesin
FYVE, Fab1p, YOTB, Vac1p and EEA1
GRAM, Glucosyltransferase, Rab-like GTPase activator, and myotubularins
LC3, microtubule associated proteins light chain 3
3-MA, 3-methyladenine
PA, phosphatidic acid
PH, pleckstrin homology
PI, phosphatidylinositol
PI3K, phosphatidylinositol-3-phosphate kinase
PIPs, phosphoinositides
PX, Phox homology
PCD, programmed cell death
SNP, single nucleotide polymorphism

References

2. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological
3. Scarlatti F, Granata R, Meijer AJ, Codogno P. Does autophagy have a license to kill mammalian cells?
   Cell Death Differ. 2008 in press
   [PubMed: 18505729]
   17671424]
   18191218]


Figure 1.
Expression of ApoL1 is inducible by interferon-γ (INF-γ) and tumor necrosis factor-α (TNF-α) in HUVEC cells. Immunoblot analysis of the time-dependent expression of ApoL1 under the influence of INF-γ and TNF-α was assayed. Hours (hrs) after treatment are as indicated. Induction of ApoL1 was detected 6 hrs and 12 hrs after INF-γ and TNF-α treatment, respectively. β-actin was used as a loading control.
MEGAALLRVSVLCIWMSALFLGVGVRAEEAEGARVQQNVPSTGDTGDPQS<KPLGDWAAGTMDESSIFIEDAIKYFKEKVSTQNLILLLTDAEAWNGFVAAAELPRNEADELRKALDNLARQMIMKDKNWHDKGQOYRNWFKLKEFPRLKSELEDNIRRMLRA

LADGVQKVHKGTITIANVVSGLSISSGILTLLVGMGLAPFT

EGGSLVLLEPGMELGITAALTGITSSTMMDYGGKWWTQAQA

HDLVIKSDLKLKEVREFLGENISNFLSLAGNTYQLTRGIG

KDIMALRRARANLQSVPHASSRPRVTISPESAESGEQVER

VNEPSILEMSRGVKLTDVAPVSFFLVLDVVLYEVESKHL

EGAKSETAEELKQAVELEEKLNILNNNYKILQADQEL

Figure 2.
Human ApoL1 and its nonsynonymous SNPs. The polypeptide sequence of ApoL1 is shown. Five newly identified NSNPs, G96R, E150K, M228I, R255K, and D337N, are indicated. The BH3 (amino acids 158–166) and leucine zipper (amino acids 365–392) domains are in bold and underlined.